These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 10941909)

  • 21. Granulocyte-colony stimulating factor enhances chimeric antibody Nd2 dependent cytotoxicity against pancreatic cancer mediated by polymorphonuclear neutrophils.
    Tamamori Y; Sawada T; Nishihara T; Yamashita Y; Ohira M; Ho JJ; Kim YS; Hirakawa-Y S Chung K
    Int J Oncol; 2002 Sep; 21(3):649-54. PubMed ID: 12168113
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunologic control of a retrovirus-associated murine adenocarcinoma. VIII. Corynebacterium parvum-activated natural killer cells as potent antibody-dependent cell-mediated cytotoxicity effectors.
    Weinhold KJ; Bolognesi DP; Matthews TJ
    J Natl Cancer Inst; 1985 Oct; 75(4):717-24. PubMed ID: 3862904
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells.
    Carson WE; Parihar R; Lindemann MJ; Personeni N; Dierksheide J; Meropol NJ; Baselga J; Caligiuri MA
    Eur J Immunol; 2001 Oct; 31(10):3016-25. PubMed ID: 11592078
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chimeric B72.3 mouse/human (IgG1) antibody directs the lysis of tumor cells by lymphokine-activated killer cells.
    Primus FJ; Pendurthi TK; Hutzell P; Kashmiri S; Slavin DC; Callahan R; Schlom J
    Cancer Immunol Immunother; 1990; 31(6):349-57. PubMed ID: 2386980
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2.
    Hank JA; Robinson RR; Surfus J; Mueller BM; Reisfeld RA; Cheung NK; Sondel PM
    Cancer Res; 1990 Sep; 50(17):5234-9. PubMed ID: 2386933
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
    Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
    Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations.
    van Ojik HH; Bevaart L; Dahle CE; Bakker A; Jansen MJ; van Vugt MJ; van de Winkel JG; Weiner GJ
    Cancer Res; 2003 Sep; 63(17):5595-600. PubMed ID: 14500400
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-β₂M monoclonal antibodies kill myeloma cells via cell- and complement-mediated cytotoxicity.
    Zhang M; Qian J; Lan Y; Lu Y; Li H; Hong B; Zheng Y; He J; Yang J; Yi Q
    Int J Cancer; 2014 Sep; 135(5):1132-41. PubMed ID: 24474467
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Absolute requirement of CD11/CD18 adhesion molecules, FcRII and the phosphatidylinositol-linked FcRIII for monoclonal antibody-mediated neutrophil antihuman tumor cytotoxicity.
    Kushner BH; Cheung NK
    Blood; 1992 Mar; 79(6):1484-90. PubMed ID: 1347707
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of effector cells in human antibody-dependent cellular cytotoxicity with murine monoclonal antibodies.
    Ortaldo JR; Woodhouse C; Morgan AC; Herberman RB; Cheresh DA; Reisfeld R
    J Immunol; 1987 May; 138(10):3566-72. PubMed ID: 2437198
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fenretinide sensitizes multidrug-resistant human neuroblastoma cells to antibody-independent and ch14.18-mediated NK cell cytotoxicity.
    Shibina A; Seidel D; Somanchi SS; Lee DA; Stermann A; Maurer BJ; Lode HN; Reynolds CP; Huebener N
    J Mol Med (Berl); 2013 Apr; 91(4):459-72. PubMed ID: 23052481
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Natural killer cell activity in the rat. VI. Characterization of rat large granular lymphocytes as effector cells in natural killer and antibody-dependent cellular cytotoxic activities.
    Fukui H; Overton WR; Herberman RB; Reynolds CW
    J Leukoc Biol; 1987 Feb; 41(2):130-42. PubMed ID: 2433376
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antitumor effect of novel anti-podoplanin antibody NZ-12 against malignant pleural mesothelioma in an orthotopic xenograft model.
    Abe S; Kaneko MK; Tsuchihashi Y; Izumi T; Ogasawara S; Okada N; Sato C; Tobiume M; Otsuka K; Miyamoto L; Tsuchiya K; Kawazoe K; Kato Y; Nishioka Y
    Cancer Sci; 2016 Sep; 107(9):1198-205. PubMed ID: 27294401
    [TBL] [Abstract][Full Text] [Related]  

  • 34. GA101 induces NK-cell activation and antibody-dependent cellular cytotoxicity more effectively than rituximab when complement is present.
    Kern DJ; James BR; Blackwell S; Gassner C; Klein C; Weiner GJ
    Leuk Lymphoma; 2013 Nov; 54(11):2500-5. PubMed ID: 23452151
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mouse immunoglobulin isotypes mediating cytotoxicity of target cells by eosinophils and neutrophils.
    López AF; Strath M; Sanderson CJ
    Immunology; 1983 Mar; 48(3):503-9. PubMed ID: 6219064
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumor-cell killing by MAbs against fucosyl GM1, a ganglioside antigen associated with small-cell lung carcinoma.
    Brezicka FT; Holmgren J; Kalies I; Lindholm L
    Int J Cancer; 1991 Dec; 49(6):911-8. PubMed ID: 1660040
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Functional activity of an HIV-1 neutralizing IgG human monoclonal antibody: ADCC and complement-mediated lysis.
    Posner MR; Elboim HS; Cannon T; Cavacini L; Hideshima T
    AIDS Res Hum Retroviruses; 1992 May; 8(5):553-8. PubMed ID: 1381201
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ocaratuzumab, an Fc-engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemia.
    Cheney CM; Stephens DM; Mo X; Rafiq S; Butchar J; Flynn JM; Jones JA; Maddocks K; O'Reilly A; Ramachandran A; Tridandapani S; Muthusamy N; Byrd JC
    MAbs; 2014; 6(3):749-55. PubMed ID: 24594909
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antibody-dependent cell-mediated cytotoxicity effector-enhanced EphA2 agonist monoclonal antibody demonstrates potent activity against human tumors.
    Bruckheimer EM; Fazenbaker CA; Gallagher S; Mulgrew K; Fuhrmann S; Coffman KT; Walsh W; Ready S; Cook K; Damschroder M; Kinch M; Kiener PA; Woods R; Gao C; Dall'Acqua W; Wu H; Coats S
    Neoplasia; 2009 Jun; 11(6):509-17, 2 p following 517. PubMed ID: 19484140
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expansion of natural killer cells in mice transgenic for IgM antibody to ganglioside GD2: demonstration of prolonged survival after challenge with syngeneic tumor cells.
    Kawashima I; Yoshida Y; Taya C; Shitara H; Yonekawa H; Karasuyama H; Tada N; Furukawa K; Tai T
    Int J Oncol; 2003 Aug; 23(2):381-8. PubMed ID: 12851687
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.